Breast Cancer Intravoxel-incoherent-motion MRI Multisite (BRIMM) Study - Resubmission - 1

项目摘要 虽然磁共振成像（MRI）的技术企业产生了大量的生物标志物， 肿瘤环境，特别是乳腺癌，很少有（通常只有一级标志物） 通过单一工作流程处理，在单中心研究之外进行测试。为了满足对先进的 组织定征和多位点平移，我们提出了一个多位点的研究体素内非相干运动 （IVIM）MRI在乳腺癌中的应用，以确定其最大的转化预后益处。IVIM模型， 包括组织细胞结构、血管体积和微血管流量的单独标记物， 该提案的项目小组将其应用于一系列癌症，包括乳腺癌。该项目将 通过硬件变化（3个供应商）和软件平台（6个）确定技术的固有可变性 包装），在临床乳腺癌IVIM数据的5个站点回顾性分析中。然后我们将进行一次 对接受新辅助化疗的患者进行前瞻性两中心IVIM纵向研究，以确定 预测治疗反应的最佳治疗前或治疗中生物标志物。在每个阶段，性能将 在每个研究中心和联合队列中进行评估，目的是确定生物标志物， 有用的和广泛的翻译。

PROJECT SUMMARY While the technological enterprise of magnetic resonance imaging (MRI) generates a host of biomarkers of the tumor environment, in particular for breast cancer, precious few (and typically only first-order markers) have been tested beyond single site studies with single workflow processing. To address both the need for advanced tissue characterization and multi-site translation, we propose a multi-site study of intravoxel incoherent motion (IVIM) MRI in breast cancer to determine its maximum translational prognostic benefit. The IVIM model, which includes separate markers of tissue cellularity, vascular volume, and micro-vascular flow, has been successfully applied in a range of cancers, including breast cancer by the project teams of this proposal. This project will determine inherent variability of the technique with hardware variation (3 vendors) and software platforms (6 packages), in a 5 site retrospective analysis of clinical breast cancer IVIM data. We will then conduct a prospective two-site IVIM longitudinal study of patients undergoing neoadjuvant chemotherapy to determine the best pre- or mid-treatment biomarkers to predict therapeutic response. At each stage, performance will be evaluated both within each site and in the combined cohort, with the goal of identifying biomarkers that are both useful and broadly translatable.